bullish
Wuxi Biologics (2269 HK) - A Monopoly in China Macromolecule CDMO
285 Views20 Jan 2021 10:01
This article analyzed WuXi Biologics in terms of market potential and position, technology platforms & R&D capability, business analysis, and profitability analysis compared with comparable company.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?03 Feb 2021
- Wuxi Biologics Placement - Laying the Groundwork for Future Growth02 Feb 2021
- China Healthcare Weekly (Jan.29)01 Feb 2021
- Wuxi Biologics (2269 HK) - A Monopoly in China Macromolecule CDMO20 Jan 2021
- Hygeia Healthcare Group (6078 HK) - Good Business Model with Large Market Potential19 Jan 2021
- Presentation for Webinar: 2021 High Conviction-Investment Opportunities in China Healthcare Industry14 Jan 2021
- Pre-IPO Basecare Medical - Here Are the the Strengths and Concerns23 Dec 2020
x